Crinetics Pharmaceuticals CRNX EBITDA margin

EBITDA margin at other companies

Neurocrine BiosciencesNBIX

26.4%+4.7pp

Corcept TherapeuticsCORT

1%-13.4pp

BridgeBio PharmaBBIO

-89.6%-40.8pp

XER

Xeris Biopharma Holdings, Inc.XERS

11.3%+8.9pp

Amylyx Pharmaceuticals, Inc.AMLX

-47,186.8%-47,246pp

Eton Pharmaceuticals, Inc.ETON

-0.6%-0.3pp

FAQ

What is Crinetics Pharmaceuticals's EBITDA margin?

Crinetics Pharmaceuticals (CRNX) reported EBITDA margin of -2,997.5% in Q1 2026.

How has Crinetics Pharmaceuticals's EBITDA margin changed year-over-year?

Crinetics Pharmaceuticals's EBITDA margin increased by 93.9% year-over-year, from -49,143.9% to -2,997.5%.

What is the long-term trend for Crinetics Pharmaceuticals's EBITDA margin?

Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EBITDA margin has grown at a -9.4% compound annual growth rate (CAGR), from -9,905.4% to -6,664.2%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.